Jeppesen P B, Staun M, Tjellesen L, Mortensen P B
Department of Medicine CA, Section of Gastroenterology 2121, Rigshospitalet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
Gut. 1998 Dec;43(6):763-9. doi: 10.1136/gut.43.6.763.
H2 receptor blockers and proton pump inhibitors reduce intestinal output in patients with short bowel syndrome.
To evaluate the effect of intravenous omeprazole and ranitidine on water, electrolyte, macronutrient, and energy absorption in patients with intestinal resection.
Thirteen patients with a faecal weight above 1.5 kg/day (range 1.7-5.7 kg/day and a median small bowel length of 100 cm were studied. Omeprazole 40 mg twice daily or ranitidine 150 mg twice daily were administered for five days in a randomised, double blind, crossover design followed by a three day control period with no treatment. Two patients with a segment of colon in continuation were excluded from analysis which, however, had no influence on the results.
Omeprazole increased median intestinal wet weight absorption compared with no treatment and ranitidine (p<0.03). The effect of ranitidine was not significant. Four patients with faecal volumes below 2.6 kg/day did not respond to omeprazole; in two absorption increased by 0.5-1 kg/day; and in five absorption increased by 1-2 kg/day. Absorption of sodium, calcium, magnesium, nitrogen, carbohydrate, fat, and total energy was unchanged. Four high responders continued on omeprazole for 12-15 months, but none could be weaned from parenteral nutrition.
Omeprazole increased water absorption in patients with faecal output above 2.50 kg/day. The effect varied significantly and was greater in patients with a high output, but did not allow parenteral nutrition to be discontinued. Absorption of energy, macronutrients, electrolytes, and divalent cations was not improved. The effect of ranitidine was not significant, possibly because the dose was too low.
H2受体阻滞剂和质子泵抑制剂可减少短肠综合征患者的肠道排泄物。
评估静脉注射奥美拉唑和雷尼替丁对肠切除患者水、电解质、大量营养素和能量吸收的影响。
研究了13例粪便重量超过1.5千克/天(范围为1.7 - 5.7千克/天,小肠中位数长度为100厘米)的患者。采用随机、双盲、交叉设计,给予患者每日两次奥美拉唑40毫克或每日两次雷尼替丁150毫克,持续五天,随后为三天的无治疗对照期。两名有连续结肠段的患者被排除在分析之外,但这对结果没有影响。
与未治疗及雷尼替丁相比,奥美拉唑增加了肠道湿重吸收中位数(p<0.03)。雷尼替丁的效果不显著。四名粪便量低于2.6千克/天的患者对奥美拉唑无反应;两名患者的吸收量增加了0.5 - 1千克/天;五名患者的吸收量增加了1 - 2千克/天。钠、钙、镁、氮、碳水化合物、脂肪和总能量的吸收未改变。四名高反应者继续使用奥美拉唑12 - 15个月,但均无法停用肠外营养。
奥美拉唑增加了粪便输出量高于2.50千克/天患者的水吸收。效果差异显著,高输出量患者的效果更明显,但不允许停用肠外营养。能量、大量营养素、电解质和二价阳离子的吸收未得到改善。雷尼替丁的效果不显著,可能是因为剂量过低。